Reuters logo
BRIEF-Alnylam announces successful outcome following FDA type A meeting
November 9, 2017 / 10:00 PM / in 12 days

BRIEF-Alnylam announces successful outcome following FDA type A meeting

Nov 9 (Reuters) - Alnylam Pharmaceuticals Inc

* Alnylam announces successful outcome following fda type a meeting to discuss fitusiran program in hemophilia

* Alignment reached with fda on amended safety measures and risk mitigation strategy to enable resumption of fitusiran clinical program​

* Reinitiation of dosing targeted around year-end​

* With completion of type a meeting, fda will now consider removal of clinical hold upon final review of amended protocols, other trial materials​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below